Clinical Trial

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

Name: A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder — clinical trial record (NCT07252908)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Protocol Amendment History 2 changes

critical Trial completed 2026-06-19

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-07

Trial Details

NCT Number	NCT07252908
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Pulmonary Disease, Chronic Obstructive
Enrollment	195 participants
Start Date	2025-12-22
Primary Completion	2026-04-28 (estimated)
Study Completion	2026-05-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-18